Aktis Oncology, Inc.

Aktis Oncology, Inc. is a clinical-stage oncology company that develops targeted radiopharmaceuticals for a wide range of cancer patients. The company aims to expand the use of targeted radiopharmaceuticals beyond current applications, which are primarily focused on prostate specific membrane antigen or somatostatin-2 receptor targets and are approved in only one tumor type each. Aktis Oncology is developing next-generation technologies to broaden the types of tumor targets that can be safely treated with alpha-emitting radioisotopes. To support its operations, Aktis Oncology is building an efficient end-to-end supply chain, combining internal capabilities with external vendors. This strategy is intended to maximize clinical utility across multiple indications and tumor types, and to expand the commercial use of radiopharmaceuticals into the broader clinical oncology setting, beyond traditional nuclear medicine. The company's core technology is a proprietary miniprotein radioconjugate platform. These miniprotein radioconjugates are engineered to selectively deliver tumor-killing radioisotopes to targeted tumors. They are designed for high tumor penetration and prolonged tumor retention, while rapidly clearing from normal organs and tissues to minimize systemic radiation exposure. Aktis Oncology's miniproteins have shown the ability to bind effectively to tumor targets that are not addressed by existing delivery technologies, such as peptide-based radioconjugates.